rs3774261 — ADIPOQ ADIPOQ rs3774261

ADIPOQ rs3774261 — When Adiponectin Goes Quiet

Adiponectin is the fat cell's best-behaved hormone: it travels from adipose tissue to muscle and liver to promote glucose uptake, suppress triglyceride synthesis, and dampen inflammation. Higher circulating levels predict lower risk of type 2 diabetes, metabolic syndrome, and cardiovascular disease¹¹ cardiovascular disease
Adiponectin acts on AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPARα), the two master switches for fatty acid oxidation and glucose metabolism. rs3774261 is an intronic variant in the ADIPOQ gene that silently influences how much of this protective hormone your fat tissue produces — and, as multiple dietary intervention trials show, how much your adiponectin level improves when you lose weight or change your diet.

The Mechanism

rs3774261 sits within an intron of ADIPOQ on chromosome 3 (GRCh38 position 186,853,770) and does not alter the amino acid sequence of adiponectin. Its effect is regulatory: the G allele is thought to reduce transcriptional activity of the ADIPOQ promoter or alter splicing efficiency of the adiponectin transcript, resulting in lower secretion from adipocytes at baseline and a blunted upregulation in response to dietary fat quality improvement or energy restriction. The downstream consequence is reduced activation of AMPK²² AMPK
AMP-activated protein kinase — the cell's main energy-sensing enzyme; activated by adiponectin; drives fatty acid oxidation and glucose uptake in muscle and PPARα in liver and muscle, which normally drives fatty acid oxidation and lowers circulating triglycerides.

The G allele is the major allele globally (~55% overall, ~62% in Europeans), so the AA genotype — the one associated with higher adiponectin — is actually the minority genotype, carried by roughly 20% of the general population.

The Evidence

The most clinically informative data comes from a series of dietary intervention trials led by de Luis and colleagues. In a 2020 study of 135 obese patients on a Mediterranean hypocaloric diet³³ Mediterranean hypocaloric diet
Calorie-restricted (−500 kcal/day) with Mediterranean dietary pattern, 12 weeks, non-G-allele carriers (AA genotype) gained +7.2 ng/dL in adiponectin after 12 weeks, while G-allele carriers showed essentially no change (−0.4 ng/dL). The lipid divergence was striking: AA carriers reduced LDL by 15.3 mg/dL and triglycerides by 23.4 mg/dL, while G carriers reduced LDL by only 1.7 mg/dL and actually increased triglycerides by 2.3 mg/dL on the same diet.

A 2021 trial⁴⁴ 2021 trial
de Luis et al., 361 obese subjects, 12-week high-PUFA hypocaloric diet confirmed the pattern: AA homozygotes reduced total cholesterol by 28.1 mg/dL, triglycerides by 35.0 mg/dL, and increased adiponectin by 11.6 ng/dL, against minimal changes in AG and GG carriers. A 2023 extension study⁵⁵ 2023 extension study
de Luis et al., 133 obese patients, 9-month MUFA Mediterranean intervention showed the same genotype-dependent divergence persisted at 9 months, with AA carriers gaining 30.1 ng/mL in adiponectin versus 7.1 ng/mL in G-allele carriers.

Upstream biological evidence is strong: a Mendelian randomization study⁶⁶ Mendelian randomization study
Gao et al. Diabetes, 2013; n=942 Swedish men from the Uppsala Longitudinal Study of Adult Men found rs3774261 among three ADIPOQ variants strongly associated with serum adiponectin (P≤5.3×10⁻⁹) and with insulin sensitivity in the expected direction (P≤0.022), supporting a causal rather than merely correlational link between adiponectin and insulin sensitivity.

Population data from the CARDIA study⁷⁷ CARDIA study
Wassel et al. Obesity, 2010; n=3,355 African-American and white participants found rs3774261 strongly associated with serum adiponectin in white participants (P=0.0001) with a dose-response relationship across genotypes. A comprehensive three-cohort meta-analysis⁸⁸ three-cohort meta-analysis
Peters et al. BMC Med Genet, 2013; n=2,355 general population + 967 type 2 diabetes confirmed rs3774261 as one of nine ADIPOQ tagSNPs significantly associated with adiponectin levels across all cohorts.

Cardiovascular relevance was shown in a case-control study in Northeast Han Chinese⁹⁹ case-control study in Northeast Han Chinese
Kanu et al. Lipids Health Dis, 2016; n=1,514: the G allele was associated with coronary heart disease risk, with a significant interaction between triglyceride levels and the SNP (P<0.0001), consistent with the triglyceride-elevating effect observed in the dietary trials.

Practical Actions

The critical practical finding is dietary fat quality modulation. Across three independent hypocaloric trials, G-allele carriers failed to raise adiponectin or improve lipids on high-fat diets that strongly benefited AA carriers. This means G-allele carriers need a different dietary strategy to achieve the same metabolic outcomes: the evidence points toward reducing saturated fat specifically in favor of unsaturated fats, and monitoring triglycerides and adiponectin directly rather than assuming weight loss alone will normalize lipid metabolism.

For monitoring, serum adiponectin is increasingly available as a direct lab test; if accessible, G-allele carriers benefit from knowing their baseline and tracking it. Fasting triglycerides and HDL-cholesterol are the standard proxies.

Interactions

rs3774261 operates in the same gene as other ADIPOQ variants with independent effects on adiponectin: rs266729 (promoter, −11391G>C), rs2241766 (3'-UTR, +45T>G), rs1501299 (intron 2, +276G>T), and rs182052 (promoter). Each tags a distinct regulatory region of ADIPOQ; individuals carrying risk alleles at multiple loci experience additive reductions in adiponectin levels. A haplotype analysis from the 2025 PCOS study found that the TG haplotype (rs1501299-rs3774261) was associated with the lowest mean adiponectin levels, suggesting synergistic regulatory suppression across introns.